ReviewImmunologic research1997
Human tumor antigens recognized by T-cells.
Review in Immunologic research, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 118 citations in OpenAlex.
- Systematic analyses of the factors influencing sperm quality in patients with SARS-CoV-2 infection.Scientific reports · 2024Article
- A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.Cancer cell · 2022Article
- Immunotherapy in breast cancer: A clinician's perspective.Journal of the National Cancer Center · 2021Review
- Cellular immunotherapy: a clinical state-of-the-art of a new paradigm for cancer treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- Humoral immune responses: Unsung heroes of the war on cancer.Seminars in immunology · 2020Review
- ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.Nagoya journal of medical science · 2019Review
- Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer.Oncology reports · 2014Article
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Glioma stem cells and immunotherapy for the treatment of malignant gliomas.ISRN oncology · 2013Article
- IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model.PloS one · 2012Article
- Cancer immunotherapy comes of age.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Review
- Immune microenvironments in solid tumors: new targets for therapy.Genes & development · 2011Review
- Article
- Article
- Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.Cancer research · 2010Article
- Profiling humoral immune responses to P. falciparum infection with protein microarrays.Proteomics · 2008Article
- T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
- A listing of human tumor antigens recognized by T cells: March 2004 update.Cancer immunology, immunotherapy : CII · 2005Review
- Allogeneic stem cell transplantation for the treatment of advanced solid tumors.Springer seminars in immunopathology · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cells play an important role in in vivo tumor rejection in many animal tumor models and in human melanoma. Many human tumor antigens recognized by autologous T-cells have now been identified. These are found to be nonmutated and mutated peptides derived from various self proteins as well as viral proteins. A variety of mechanisms involved in generating these T-cell epitopes on growing cancers have also been identified. However, the role of these identified antigens remains to be evaluated. Passive or active immunotherapies using these identified tumor antigens are being conducted in many institutions. The results obtained from these clinical trials may give us better insight into the role of T-cell responses to each antigen in tumor rejection as well as the development of new antigen-specific immunotherapies for patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.